欧美日本一道本一区二区_亚洲免费影视_91手机在线看片_精品欧美成人高清在线观看_少妇作爱bbbb免费看_51久久夜色精品国产水果派解说

Ambit Biosciences  
生物制藥公司，致力于發(fā)現(xiàn)，開發(fā)和商業(yè)化的藥物來治療腫瘤，自身免疫性疾病和炎癥性疾病

Ambit Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Our pipeline currently includes three programs, each aimed at the inhibition of validated kinase targets.

Our lead drug candidate, quizartinib, is a once-daily, orally-administered, potent and selective inhibitor of FMS-like tyrosine kinase 3 (FLT3), a validated target in the treatment of AML, and is currently in Phase 2b clinical development in relapsed/refractory AML patients who express the FLT3-ITD mutation (FLT3-ITD positive patients). The FLT3-ITD mutation acts like a “power switch” that causes leukemic cells, or blasts, to spread more aggressively and grow back more rapidly following chemotherapy, conferring an especially poor survival outcome. Quizartinib is designed to turn off this switch.

Our second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases.

Our third program consists of a potent and exquisitely selective small molecule compound, AC708, which inhibits the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase. This compound is in preclinical studies and has potential utility in oncology, autoimmune and inflammatory diseases. All of our drug candidates and clinical candidates have been internally discovered by us.